Yagasaki Yuki, Numakawa Tadahiro, Kumamaru Emi, Hayashi Teruo, Su Tsung-Ping, Kunugi Hiroshi
Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo 187-8502, Japan.
J Biol Chem. 2006 May 5;281(18):12941-9. doi: 10.1074/jbc.M508157200. Epub 2006 Mar 6.
Up-regulation of BDNF (brain-derived neurotrophic factor) has been suggested to contribute to the action of antidepressants. However, it is unclear whether chronic treatment with antidepressants may influence acute BDNF signaling in central nervous system neurons. Because BDNF has been shown by us to reinforce excitatory glutamatergic transmission in cultured cortical neurons via the phospholipase-gamma (PLC-gamma)/inositol 1,4,5-trisphosphate (IP3)/Ca2+ pathway (Numakawa, T., Yamagishi, S., Adachi, N., Matsumoto, T., Yokomaku, D., Yamada, M., and Hatanaka, H. (2002) J. Biol. Chem. 277, 6520-6529), we examined in this study the possible effects of pretreatment with antidepressants on the BDNF signaling through the PLC-gamma)/IP3/Ca2+ pathway. Furthermore, because the PLC-gamma/IP3/Ca2+ pathway is regulated by sigma-1 receptors (Hayashi, T., and Su, T. P. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 491-496), we examined whether the BDNF signaling is modulated by sigma-1 receptors (Sig-1R). We found that the BDNF-stimulated PLC-gamma activation and the ensued increase in intracellular Ca2+ ([Ca2+]i) were potentiated by pretreatment with imipramine or fluvoxamine, so was the BDNF-induced glutamate release. Furthermore, enhancement of the interaction between PLC-gamma and TrkB (receptor for BDNF) after imipramine pretreatment was observed. Interestingly, BD1047, a potent Sig-1R antagonist, blocked the imipramine-dependent potentiation on the BDNF-induced PLC-gamma activation and glutamate release. In contrast, overexpression of Sig-1R per se, without antidepressant pretreatment, enhances BDNF-induced PLC-gamma activation and glutamate release. These results suggest that antidepressant pretreatment selectively enhance the BDNF signaling on the PLC-gamma/IP3/Ca2+ pathway via Sig-1R, and that Sig-1R plays an important role in BDNF signaling leading to glutamate release.
脑源性神经营养因子(BDNF)的上调被认为有助于抗抑郁药发挥作用。然而,目前尚不清楚长期使用抗抑郁药是否会影响中枢神经系统神经元中的急性BDNF信号传导。由于我们已经证明BDNF可通过磷脂酶γ(PLC-γ)/肌醇1,4,5-三磷酸(IP3)/Ca2+途径增强培养的皮质神经元中的兴奋性谷氨酸能传递(沼川,T.,山岸,S.,安达,N.,松本,T.,横幕,D.,山田,M.,和畑中,H.(2002年)《生物化学杂志》277,6520-6529),因此我们在本研究中检测了用抗抑郁药预处理对通过PLC-γ/IP3/Ca2+途径的BDNF信号传导的可能影响。此外,由于PLC-γ/IP3/Ca2+途径受σ1受体调节(林,T.,和苏,T.P.(2001年)《美国国家科学院院刊》98,491-496),我们检测了BDNF信号传导是否受σ1受体(Sig-1R)调节。我们发现,用丙咪嗪或氟伏沙明预处理可增强BDNF刺激的PLC-γ激活以及随后细胞内Ca2+([Ca2+]i)的增加,BDNF诱导的谷氨酸释放也是如此。此外,观察到丙咪嗪预处理后PLC-γ与TrkB(BDNF受体)之间的相互作用增强。有趣的是,强效σ1受体拮抗剂BD1047可阻断丙咪嗪对BDNF诱导的PLC-γ激活和谷氨酸释放的增强作用。相反,在未用抗抑郁药预处理的情况下,σ1受体的过表达本身可增强BDNF诱导的PLC-γ激活和谷氨酸释放。这些结果表明,抗抑郁药预处理通过σ1受体选择性增强PLC-γ/IP3/Ca2+途径上的BDNF信号传导,并且σ1受体在导致谷氨酸释放的BDNF信号传导中起重要作用。